KA
RPRX icon

Keene & Associates’s Royalty Pharma RPRX Stock Holding History

Keene & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$495K Buy
19,420
+370
+2% +$9.81K 0.4% 52
2024
Q3 		$539K Buy
+19,050
New +$528K 0.41% 46

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Keene & Associates's RPRX Position: Q4 2024 in Review

Keene & Associates increased its Royalty Pharma (RPRX) stake by 1.9% in Q4 2024, buying an estimated $9.81K and bringing the position to 19,420 shares worth $495K. The position accounts for 0.4% of the portfolio, ranked #52.

Keene & Associates first reported a position in RPRX in Q3 2024 and has held it in 2 quarters since. The position peaked at $539K in Q3 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Keene & Associates held 19,420 shares of Royalty Pharma worth $495K as of Q4 2024.
  • Keene & Associates bought 370 Royalty Pharma shares in Q4 2024, an estimated $9.81K.
  • Royalty Pharma made up 0.4% of Keene & Associates's portfolio in Q4 2024, its #52 holding.
  • Keene & Associates first reported a position in Royalty Pharma in Q3 2024 and has held it in 2 quarters since.
  • Keene & Associates's Royalty Pharma position peaked at $539K in Q3 2024.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.